EXPLORINEER
en

Archive — US — techcrunch

AI is spitting out more potential drugs than ever. This start-up wants to figureout which ones matter.

10x Science, a startup founded in December 2025, raised $4.8 million to address the bottleneck in drug development by characterizing AI-generated drug candidates. Founded by experienced biochemists and a tech entrepreneur, their platform combines algorithms with AI to analyze complex protein structures, facilitating better understanding and regulatory compliance in biopharma research.

Key points

  • 10x Science was founded in December 2025 with a mission to characterize drug candidates generated by AI.
  • The startup raised $4.8 million in seed funding, led by Initialized Capital and supported by Y Combinator.
  • Founders David Roberts and Andrew Reiter are experienced biochemists, while Vishnu Tejas specializes in computer science and AI.
  • They aim to streamline the drug characterization process, a critical step in biopharma where effective predictions can overwhelm existing testing capabilities.
  • Their platform utilizes deterministic algorithms combined with AI to interpret mass spectrometry data, a complex method of analyzing molecular structures.
  • The technology is designed for regulatory compliance and offers a traceable analysis for biopharma companies.
  • 10x Science is currently collaborating with large pharmaceutical companies and holds promise for application in academic research.

Why it matters

  • Advancements in AI and drug development have been accelerating, shaping the future of biopharma.
  • The rise of machine learning in biology parallels trends in personalized medicine and targeted therapies.
  • Mass spectrometry is gaining importance in biotech, with new tools that enhance how researchers analyze complex data.
  • This development reflects a growing trend towards integrating AI to increase efficiency in scientific research and drug discovery.

10x Science is positioned to significantly impact biopharma by optimizing the characterization of AI-generated drug candidates, indicating a transformative phase in the industry fueled by technological advancements in data analysis.